SG11201901851YA - Wound healing peptide - Google Patents
Wound healing peptideInfo
- Publication number
- SG11201901851YA SG11201901851YA SG11201901851YA SG11201901851YA SG11201901851YA SG 11201901851Y A SG11201901851Y A SG 11201901851YA SG 11201901851Y A SG11201901851Y A SG 11201901851YA SG 11201901851Y A SG11201901851Y A SG 11201901851YA SG 11201901851Y A SG11201901851Y A SG 11201901851YA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- peptide
- queensland
- pct
- wound healing
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 7
- 230000029663 wound healing Effects 0.000 title abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 3
- 230000004663 cell proliferation Effects 0.000 abstract 2
- 108060003393 Granulin Proteins 0.000 abstract 1
- 230000012292 cell migration Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 102000017941 granulin Human genes 0.000 abstract 1
- 238000013508 migration Methods 0.000 abstract 1
- YIEDSISPYKQADU-UHFFFAOYSA-N n-acetyl-n-[2-methyl-4-[(2-methylphenyl)diazenyl]phenyl]acetamide Chemical compound C1=C(C)C(N(C(C)=O)C(=O)C)=CC=C1N=NC1=CC=CC=C1C YIEDSISPYKQADU-UHFFFAOYSA-N 0.000 abstract 1
- 210000004897 n-terminal region Anatomy 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 abstract 1
- 230000001737 promoting effect Effects 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43536—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms
- C07K14/43559—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms from trematodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
A) C-terminus () INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 08 March 2018 (08.03.2018) W I PO I PCT omit VIII °nolo oui oo1 110 iflo oimIE (10) International Publication Number WO 2018/039748 Al (51) International Patent Classification: C07K 14/475 (2006.01) A61P 43/00 (2006.01) A61K 38/18 (2006.01) (21) International Application Number: PCT/AU2017/050959 (22) International Filing Date: 04 September 2017 (04.09.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 2016903523 02 September 2016 (02.09.2016) AU 2016905327 22 December 2016 (22.12.2016) AU (71) Applicant: JAMES COOK UNIVERSITY [AU/AU]; Townsville, Queensland 4811 (AU). (72) Inventors: LOUKAS, Alex; Townsville, Queensland 4811 (AU). SMOUT, Michael; 14 McGregor Rd, James Cook University, Building E4.103, Smithfield, QLD 4878 (AU). DALY, Norelle; 7 Catamaran Circuit, Trinity Beach, QLD 4879 (AU). (74) Agent: FISHER ADAMS KELLY CALLINANS; Level 6, 175 Eagle Street, Brisbane, Queensland 4000 (AU). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). (54) Title: WOUND HEALING PEPTIDE Figure 1 II EEI V V V VIE VIIE EX X XE xit -c -CC.-cc-CC-ccmc -c I (57) : Peptides derived from the N-terminal region of granulin have activity in promoting cell proliferation, migration and/ or wound healing. Furthermore, an additional disulphide bond may be engineered into such peptides to improve or otherwise modify the folding of the peptide. The peptides may also be modified such as at proline residues improve the ability of the peptide to promote cell proliferation. [Continued on next page] WO 2018/039748 Al MIDEDIMOMMIDEFIERIMEOCIENIEHMOVOIMIE Published: — with international search report (Art. 21(3))
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2016903523A AU2016903523A0 (en) | 2016-09-02 | Wound healing peptide | |
| AU2016905327A AU2016905327A0 (en) | 2016-12-22 | Wound healing peptide | |
| PCT/AU2017/050959 WO2018039748A1 (en) | 2016-09-02 | 2017-09-04 | Wound healing peptide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201901851YA true SG11201901851YA (en) | 2019-03-28 |
Family
ID=61299632
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201901851YA SG11201901851YA (en) | 2016-09-02 | 2017-09-04 | Wound healing peptide |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20190194279A1 (en) |
| EP (1) | EP3507300B1 (en) |
| JP (2) | JP7186451B2 (en) |
| KR (1) | KR102570921B1 (en) |
| CN (1) | CN109890836B (en) |
| AU (1) | AU2017322098C1 (en) |
| BR (1) | BR112019004337A2 (en) |
| CA (1) | CA3035371A1 (en) |
| DK (1) | DK3507300T3 (en) |
| ES (1) | ES2940418T3 (en) |
| FI (1) | FI3507300T3 (en) |
| IL (1) | IL265130B2 (en) |
| MX (1) | MX2019002497A (en) |
| PL (1) | PL3507300T3 (en) |
| SG (1) | SG11201901851YA (en) |
| WO (1) | WO2018039748A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110903377B (en) * | 2019-11-08 | 2021-03-23 | 上海交通大学 | Bioactive polypeptide IGCDQHTSCPVGQTCCPS, and preparation method and application thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU1325792A (en) | 1992-02-03 | 1993-09-01 | Samuel Solomon | Granulins from leukocytes |
| AUPO007396A0 (en) | 1996-05-24 | 1996-06-20 | Csl Limited | Ebv ctl epitopes |
| AUPO784197A0 (en) | 1997-07-10 | 1997-08-07 | Csl Limited | Treatment of nasopharyngeal carcinoma |
| US7427595B1 (en) * | 2002-12-12 | 2008-09-23 | Cornell Research Foundation, Inc. | Use of proepithelin to promote wound repair and reduce inflammation |
| WO2022164978A1 (en) * | 2021-01-27 | 2022-08-04 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Method of treating corneal opacities and scarring |
-
2017
- 2017-09-04 SG SG11201901851YA patent/SG11201901851YA/en unknown
- 2017-09-04 PL PL17844710.8T patent/PL3507300T3/en unknown
- 2017-09-04 IL IL265130A patent/IL265130B2/en unknown
- 2017-09-04 AU AU2017322098A patent/AU2017322098C1/en active Active
- 2017-09-04 CN CN201780067257.0A patent/CN109890836B/en active Active
- 2017-09-04 CA CA3035371A patent/CA3035371A1/en active Pending
- 2017-09-04 DK DK17844710.8T patent/DK3507300T3/en active
- 2017-09-04 JP JP2019533258A patent/JP7186451B2/en active Active
- 2017-09-04 US US16/329,800 patent/US20190194279A1/en active Pending
- 2017-09-04 FI FIEP17844710.8T patent/FI3507300T3/en active
- 2017-09-04 KR KR1020197009205A patent/KR102570921B1/en active IP Right Grant
- 2017-09-04 ES ES17844710T patent/ES2940418T3/en active Active
- 2017-09-04 BR BR112019004337A patent/BR112019004337A2/en not_active IP Right Cessation
- 2017-09-04 EP EP17844710.8A patent/EP3507300B1/en active Active
- 2017-09-04 WO PCT/AU2017/050959 patent/WO2018039748A1/en unknown
- 2017-09-04 MX MX2019002497A patent/MX2019002497A/en unknown
-
2022
- 2022-07-29 JP JP2022121743A patent/JP2022161922A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR102570921B1 (en) | 2023-08-25 |
| KR20190080860A (en) | 2019-07-08 |
| AU2017322098C1 (en) | 2024-04-11 |
| ES2940418T3 (en) | 2023-05-08 |
| CN109890836A (en) | 2019-06-14 |
| US20190194279A1 (en) | 2019-06-27 |
| EP3507300A4 (en) | 2020-04-08 |
| EP3507300A1 (en) | 2019-07-10 |
| JP2019531089A (en) | 2019-10-31 |
| CA3035371A1 (en) | 2018-03-08 |
| JP7186451B2 (en) | 2022-12-09 |
| IL265130B2 (en) | 2024-02-01 |
| IL265130A (en) | 2019-04-30 |
| DK3507300T3 (en) | 2023-03-27 |
| EP3507300B1 (en) | 2022-12-28 |
| AU2017322098A1 (en) | 2019-04-18 |
| MX2019002497A (en) | 2019-08-14 |
| FI3507300T3 (en) | 2023-04-03 |
| CN109890836B (en) | 2024-04-19 |
| WO2018039748A1 (en) | 2018-03-08 |
| PL3507300T3 (en) | 2023-07-03 |
| BR112019004337A2 (en) | 2019-05-28 |
| IL265130B1 (en) | 2023-10-01 |
| AU2017322098B2 (en) | 2021-12-23 |
| JP2022161922A (en) | 2022-10-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201807286WA (en) | Methods and compositions for transducing lymphocytes and regulated expansion thereof | |
| SG11201804038VA (en) | Conditionally active heterodimeric polypeptides and methods of use thereof | |
| SG11201901528RA (en) | Proteolytically cleavable chimeric polypeptides and methods of use thereof | |
| SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
| SG11201806398YA (en) | Optimized factor viii genes | |
| SG11201909728XA (en) | Constructs specifically recognizing glypican 3 and uses thereof | |
| SG11201903454VA (en) | Immunologically discernible cell surface variants for use in cell therapy | |
| SG11201908624SA (en) | Aryl hydrocarbon receptor antagonists and uses thereof | |
| SG11201900746RA (en) | Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions | |
| SG11201805451TA (en) | Immune effector cell therapies with enhanced efficacy | |
| SG11201808196UA (en) | Neoantigens and methods of their use | |
| SG11201807252QA (en) | Anti-lag-3 antibodies | |
| SG11201906468TA (en) | Chimeric antigen receptors against axl or ror2 and methods of use thereof | |
| SG11201805709RA (en) | Anti-pro/latent myostatin antibodies and methods of use thereof | |
| SG11201903450YA (en) | Methods for treating muscle wasting and bone disease using novel hybrid actriib ligand trap proteins | |
| SG11201809374VA (en) | Cd40l-fc fusion polypeptides and methods of use thereof | |
| SG11202000312UA (en) | Encapsulated polynucleotides and methods of use | |
| SG11201908238SA (en) | Anti-c5 antibodies and uses thereof | |
| SG11201408746XA (en) | Novel prime-boosting regimens involving immunogenic polypeptides encoded by polynucleotides | |
| SG11201407200TA (en) | Liquid formulation | |
| SG11201808949SA (en) | Combinations and methods comprising a capsid assembly inhibitor | |
| SG11201907420VA (en) | Inhibition of smarca2 for treatment of cancer | |
| SG11201806788TA (en) | Endoscopic systems, devices, and methods | |
| SG11201810687SA (en) | Serum albumin-binding fibronectin type iii domains | |
| SG11201909003YA (en) | Integrated vascular access device and anchor pad |